IQVIA Introduces Life Science Models for Predicting Clinical Trial Outcomes
Research Triangle Park, N.C. — IQVIA (NYSE:IQV), a leader in clinical research services and healthcare intelligence, unveiled its new IQVIA Life Science Models™ at TechIQ 2026. These models are designed to enhance the prediction of clinical trial outcomes.
Key Features of IQVIA Life Science Models:
-
Clinical Study Simulation:
- Optimizes protocols by selecting endpoints, patient eligibility, dosing, and sample size.
- In initial tests, 85% of predictions were accurate or close to actual outcomes.
-
Digital Twins & Synthetic Controls:
- Facilitate more efficient study design.
-
Real-World Planning:
- Predictions help in planning and improving patient access.
Pete Groves, EVP of AI & Technology Solutions at IQVIA, stated, “Customers can essentially run the trial before it happens, helping anticipate outcomes and speeding therapy delivery.”
The Life Science Models extend IQVIA’s Predictive Clinical Development approach, allowing sponsors to simulate studies, test assumptions, and optimize design before execution.
For more details, visit IQVIA Life Science Models.
About IQVIA
IQVIA is a global provider in clinical research and healthcare intelligence, leveraging AI, analytics, and extensive domain expertise to improve patient outcomes. With about 94,000 employees, IQVIA is committed to maintaining high standards in privacy and regulatory compliance while advancing medical treatments.
For media inquiries, contact:
- Kerri Joseph: kerri.joseph@iqvia.com | +1.973.541.3558
- Alissa Maupin: alissa.maupin1@iqvia.com | +1.919.923.6785
Learn more at www.iqvia.com.
